Drug Eruption and Interactions - PHARMACEUTICAL REVIEW

Other
Anaphylactoid reactions/Anaphylaxis
(1993): Tarlo SM+, Can Fam Physician 39, 1119
(1989): Montano Garcia ML, Rev Alerg Mex 36(3), 107
Neurotoxicity
(1982): Freed DL+, Ann Allergy 48(2), 96
Note: The US Food & Drug Administration has determined that
MSG is a safe food ingredient if used in moderation. Only a very small
subset of individuals is allergic to MSG
MONTELUKAST
Trade name: Singulair (Merck)
Indications: Asthma
Category: Leukotriene receptor antagonist
Half-life: 2.7–5.5 hours
Clinically important, potentially hazardous interactions
with: boswellia, prednisone
Reactions
Skin
Allergic granulomatous angiitis (Churg-Strauss syndrome)
(2007): Guilpain P+, Presse Med 36(5 Pt 2), 890
(2007): Zandman-Goddard G+, Isr Med Assoc J 9(1), 50
(2004): Boccagni C+, Neurol Sci 25(1), 21
(2004): Conen D+, Swiss Med Wkly 134(25–26), 377
(2004): Oberndorfer S+, Neurologia 19(3), 134
(2003): Michael AB+, Age Ageing 32(5), 551
(2003): Turvey SE+, Ann Allergy Asthma Immunol 90(2), 274
(2002): Alvarez-Fernandez JG+, World Congress Dermatol
Poster, 0082
(2002): Gal AA+, Br J Dermatol 147(3), 618
(2002): Guilpain P+, Rheumatology (Oxford) 41(5), 535 (2 cases)
(2002): Hammer HB+, Tidsskr Nor Laegeforen 122(5), 484
(2002): Jamaleddine G+, Semin Arthritis Rheum 31(4), 218
(2002): Mateo ML+, Arch Bronconeumol 38(1), 56
(2002): Perez de Llano LA+, Arch Bronconeumol 38(5), 251
(2002): Solans R+, Thorax 57(2), 183 (1 case)
(2001): Donohue J, Chest 119(2), 668
(2001): Hosker HS, Thorax 56(3), 244
(2001): Kalyoncu A+, Allergol Immunopathol (Madr) 29(5), 185
(2001): Lipworth BJ+, Thorax 56(3), 244
(2001): Mukhopadhyay A+, Postgrad Med J 56(5), 417
(2001): Sabio JM+, Chest 120(6), 2116
(2001): Weschler M Thorax, Thorax 56(5), 417
(2002): Perez de Llano LA+, Arch Bronconeumol 38(5), 251
(2000): Can Fam Physician 46, 86
(2000): Price D, Drugs 59, 35 (passim)
(2000): Trujillo-Santos AJ+, Med Clin (Barc) 115(15), 599
(2000): Tuggey JM+, Thorax 55(9), 805
(2000): Villena V+, Eur Resp J 15, 626
(2000): Wechsler ME+, Chest 117, 708
(1999): Prescrire Int 8(43), 131
(1999): Franco J+, Thorax 54(6), 558
(1999): Wechsler ME+, Drug Saf 21(4), 241
Angioedema
(1998): Condry P, Webster, NY (from Internet) (observation)
Erythema nodosum
(2000): Dellaripa PF+, Mayo Clin Proc 75(6), 643
Henoch–Schonlein purpura
(2005): Khanna S+, Indian J Gastroenterol 24(2), 86
Pemphigus
(2003): Cetkovska P+, Clin Exp Dermatol 28(3), 328
Peripheral edema
(2000): Geller M, AnnInternMed132, 924
Rash (sic) (1.6%)
Urticaria (1.6%)
(1998): Jaffe P, Columbia, SC (from Internet) (observation)
(1998): Knorr B+, JAMA 279, 1181
Other
Cough
(2001): Spector SL, Ann Allergy Asthma Immunol 86(6 Suppl 1), 18
Panniculitis
(2000): Dellaripa PF+, Mayo Clin Proc 75(6), 643
MORICIZINE
Trade name: Ethmozine (Shire)
Indications: Ventricular arrhythmias
Category: Antiarrhythmic class 1c
Half-life: 3–4 hours
Clinically important, potentially hazardous interactions
with: diltiazem, warfarin
Reactions
Skin
Diaphoresis (2–5%)
Exanthems (